Chapter 37 AkaRx Company personally visited!
The price of "Eltrombopag" dropped from 2,600 yuan per box to 1,000 yuan per box in three months, which directly became the last straw for domestic generic "Eltrombopag" pharmaceutical companies.
At noon the next day, Beifeng Pharmaceutical had to cut off its arm to survive. The original price of "Eltrombopag" of 1,700 yuan dropped by 1,000 yuan. The latest price has dropped to 700 yuan. At the same time, Beifeng Pharmaceutical The industry has also begun to take the initiative to express its goodwill, hoping to be added to the medical insurance directory!
At this point, the prices of first-line and second-line treatment drugs for blood diseases in China have been reduced across the board.
While "Elqupopa" was struggling to find a living space, the AkaRx company on the other side of the ocean held an emergency meeting.
There was only one theme of the meeting, and that was how to deal with Chinese companies pricing "Qingshan Avatrombopag Tablets" at 1,599 yuan.
“Let me tell you my point of view first. I don’t agree with price cuts or price wars.”
“Let’s look at a set of data first. Last year we sold a total of ‘Ava’ in the Chinese market. There are 160,000 boxes of Trombopag tablets, and the sales amount reaches 1.26 billion yuan.
If we follow the price reduction of Qingshan Pharmaceutical, the initial estimate is. According to the calculation, even if the total sales volume remains unchanged, the total sales amount will plummet to only 350 million, and most importantly, our sales profit margin will plummet to only 400%.”
“This! The profit margin is the lowest in any market we are in, so I firmly disagree with the price reduction!”
The so-called market in the world means that multinational pharmaceutical companies will set the sales price of drugs in different countries or regions based on the actual local conditions.
Some countries sell it cheaper, and some countries sell it more expensive.
“Sir, I understand your feelings, but you have to understand that the reason why we can sell it so expensively in other markets is because other countries do not have drugs like Qingshan Avatrombopag Tablets to compete with us. Of course we can unscrupulously sell more than High profits, but not anymore, at least not in the Chinese market..."
"Then quit, the price is not even as low as ours in the United States, they don't deserve it! These Orientals don't deserve it!"< br>
Exit the Chinese market?
Mike, the white man who had just retorted, couldn't help but shook his head with a wry smile, and even the conference room suddenly fell into silence.
As we all know, the Chinese market is famous for its stupid people and a lot of money, especially in the pharmaceutical industry. The world's major well-known pharmaceutical companies have completely crushed China's local pharmaceuticals. Each imported original research product requires not only The sales are very good, and the price in the Chinese market is higher than that in other countries.
Take "Avatrombopag Tablets" as an example.
Last year, the Chinese market contributed 35% of AkaRx’s global profits. Who would be willing to give up on such a market easily?
At this moment, a middle-aged white man sitting in the middle of the conference table lightly knocked on the table, breaking the silence.
He looked at the man who spoke first:
“Although Huaxia Pharmaceutical’s ‘Qingshan Avatrombopag Tablets’ has indeed caused us a lot of trouble, we have not yet reached the point where we want to withdraw from the Huaxia market. ”
“And. Moreover, I just got the news that Qingshan Pharmaceutical has set the price of 'Avatrombopag Tablets' at 1,599 yuan, probably because of official pressure."
"Official pressure?"
“That’s right.”
The middle-aged white man in the middle nodded and continued:
"Just now our sales partner in China, Fuxing Pharmaceutical, sent us a more detailed information. Qingshan Pharmaceutical finally chose Qingshan Pharmaceutical because of lack of funds. Apply to join the 'Grain Seedling Project', which is an official organization of China
Even though Tsingshan Pharmaceutical said so righteously at the press conference, they believe that all this is probably from official arrangements, and the price of 1,599 yuan is not that of Tsingshan Pharmaceutical. The original intention.”
After the words fell, everyone in the audience fell into thinking.
After a while, Mike, the white man who just spoke, took the lead in nodding.
"If that's the case, it makes sense."
"According to my understanding of Chinese officials, their medical insurance pressure is indeed very high, and they are now unable to make ends meet, like 'Qingshan Avatrombopag' If the drug enters the 'Grain Miao Project', they will inevitably lower the purchase price at all costs."
"So, I also think that 1,599 yuan should be the result of their game." After that, another person also raised his hand. Come on.
“I also agree with Mike’s statement, and I just noticed a detail that Qingshan Pharmaceutical was forced to join the ‘Grain Miao Project’ due to lack of funds. I believe that the more experience People who are short of funds will pay more and more attention to profits. ”
"They have worked so hard to finally put it on the market. They don't just want to make such a small profit from Weibo. This price is definitely not what they really want."
"That's right! I agree too!
In this case, I think we can have sex with him Let’s talk, as long as we reach an agreement with them privately, even with the pressure from the Chinese officials, we can jointly monopolize the market and keep most of the profits!”
After the words fell, everyone looked at each other! They all looked at the middle-aged white man in the middle of the conference table.
After a moment, the middle-aged white man nodded slightly:
"Yes!"
"In the end, Qingshan Pharmaceutical is just a private pharmaceutical company. Since it is a businessman, it has to make money and eat. I don't believe they will refuse in the face of huge profits!"
......
AkaRx company is very efficient. Early the next morning, Zhang Yang received a business call from Sino-Ocean AkaRx company.
“I really didn’t expect AkaRx to become restless so quickly and actually called us personally hoping to meet and talk with us.”
In the office, Zhang Yang shared with Ren Xiaomin the call he received from AkaRx half an hour ago with some emotion.
Ren Xiaomin was not surprised and said with a smile:
"You're just kidding, your pricing has dug the roots of AkaRx. It's strange that they are not in a hurry."
>After that, he filled Zhang Yang with tea and then refilled himself:
"What happened in the end? Do you decide to meet?"
"Yeah."
Zhang Yang nodded.
If it had been before, he might have refused directly. What would the competitor have to say?
But after experiencing so many things, especially after several confrontations with Beifeng Pharmaceutical, he has matured a lot.
"Since they have all taken the initiative to call and ask to meet, let's meet. It will also be a good time to see what they want. Then you can go with me."
"Yeah, okay."
Zhang Yang readily agreed, which made AkaRx even more excited and more certain of his judgment.
On the third day, Mike, the executive vice president of AkaRx and the business leader of the China region, arrived in Chengdu in person, accompanied by Gao Qiang, an executive from Fuxing Pharmaceuticals.
The meeting between the two parties was scheduled in a business hotel in Chengdu. As soon as they met, the two were slightly shocked by Zhang Yang's youth, but soon the meeting got down to business.
"Zhang, please excuse me, we are here today to have a good talk about cooperation with you."
(End of this chapter)